CL2014001966A1 - Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica. - Google Patents

Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.

Info

Publication number
CL2014001966A1
CL2014001966A1 CL2014001966A CL2014001966A CL2014001966A1 CL 2014001966 A1 CL2014001966 A1 CL 2014001966A1 CL 2014001966 A CL2014001966 A CL 2014001966A CL 2014001966 A CL2014001966 A CL 2014001966A CL 2014001966 A1 CL2014001966 A1 CL 2014001966A1
Authority
CL
Chile
Prior art keywords
fraction
dry powder
dihydrate
asthma
prevention
Prior art date
Application number
CL2014001966A
Other languages
English (en)
Inventor
Elisa Monari
Anna Maria Cantarelli
Daniela Cocconi
Irene Pasquali
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of CL2014001966A1 publication Critical patent/CL2014001966A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
CL2014001966A 2012-01-25 2014-07-24 Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica. CL2014001966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25

Publications (1)

Publication Number Publication Date
CL2014001966A1 true CL2014001966A1 (es) 2014-11-14

Family

ID=47715987

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001966A CL2014001966A1 (es) 2012-01-25 2014-07-24 Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.

Country Status (38)

Country Link
US (3) US10028964B2 (es)
EP (7) EP3527196B1 (es)
JP (1) JP6104282B2 (es)
KR (3) KR101786586B1 (es)
CN (2) CN105726548B (es)
AR (1) AR089805A1 (es)
AU (1) AU2013211656B2 (es)
BR (1) BR112014017481A8 (es)
CA (1) CA2862548C (es)
CL (1) CL2014001966A1 (es)
CO (1) CO7010836A2 (es)
CY (1) CY1120684T1 (es)
DK (5) DK3527197T3 (es)
EA (2) EA026267B1 (es)
ES (5) ES2928688T3 (es)
FI (1) FI3412277T3 (es)
GE (1) GEP201706767B (es)
HK (1) HK1200021A1 (es)
HR (5) HRP20221433T1 (es)
HU (5) HUE061566T2 (es)
IL (1) IL233784A0 (es)
LT (5) LT3527197T (es)
MA (1) MA35859B1 (es)
MX (2) MX368199B (es)
MY (1) MY165888A (es)
NZ (1) NZ627837A (es)
PE (1) PE20141703A1 (es)
PH (1) PH12014501565A1 (es)
PL (5) PL2806855T3 (es)
PT (5) PT3412277T (es)
RS (5) RS63706B1 (es)
SG (1) SG11201404350PA (es)
SI (2) SI2806855T1 (es)
TN (1) TN2014000322A1 (es)
TW (1) TWI559940B (es)
UA (1) UA115543C2 (es)
WO (1) WO2013110632A1 (es)
ZA (1) ZA201405464B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101786586B1 (ko) * 2012-01-25 2017-10-18 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
PE20212110A1 (es) 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
CN107205936B (zh) 2014-10-08 2021-07-16 萨宝公司 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
EP3687500A1 (en) * 2017-09-29 2020-08-05 Crititech, Inc. Glucocorticoid particles and their use
US11774363B2 (en) * 2018-08-07 2023-10-03 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
US20210370007A1 (en) 2018-10-30 2021-12-02 Chiesi Farmaceuticl S.p.A. Apparatus to administer drugs to mechanically ventilated patients
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
EP4196105A1 (en) 2020-08-14 2023-06-21 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ATE382386T1 (de) 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
DK1386630T3 (da) 2002-07-31 2006-09-11 Chiesi Farma Spa Pulverinhalator
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
RS53514B1 (en) * 2009-10-02 2015-02-27 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL AEROSOL FORMOTEROL FORMULATION AND BECLOMETHASONE DIPROPIONATE
CA2794941C (en) 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
UA111470C2 (uk) 2010-04-21 2016-05-10 К'Єзі Фармачеутічі С.П.А. Спосіб отримання частинок зі зменшеними електростатичними зарядами
KR101786586B1 (ko) * 2012-01-25 2017-10-18 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
PE20212110A1 (es) * 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion

Also Published As

Publication number Publication date
PT3412277T (pt) 2023-02-14
EP3412277B1 (en) 2022-12-14
EA201491281A1 (ru) 2014-12-30
ES2928688T3 (es) 2022-11-22
RS63706B1 (sr) 2022-11-30
ES2683254T3 (es) 2018-09-25
EP3527196B1 (en) 2022-09-07
LT2806855T (lt) 2018-10-10
RS63759B1 (sr) 2022-12-30
TWI559940B (en) 2016-12-01
PL3527197T3 (pl) 2022-11-21
HUE040525T2 (hu) 2019-03-28
AU2013211656A1 (en) 2014-07-24
TW201334810A (zh) 2013-09-01
GEP201706767B (en) 2017-11-10
US20130189324A1 (en) 2013-07-25
UA115543C2 (uk) 2017-11-27
ES2938466T3 (es) 2023-04-11
EA201690187A1 (ru) 2016-05-31
CA2862548C (en) 2020-07-07
PT3527196T (pt) 2022-10-18
LT3527196T (lt) 2022-11-25
LT3527199T (lt) 2022-12-12
PL2806855T3 (pl) 2018-12-31
EP3527198A1 (en) 2019-08-21
PT2806855T (pt) 2018-09-28
CA2862548A1 (en) 2013-08-01
KR101895279B1 (ko) 2018-09-05
MX368199B (es) 2019-09-24
PL3527199T3 (pl) 2022-12-12
KR20170116234A (ko) 2017-10-18
EP2806855B1 (en) 2018-07-11
ES2929807T3 (es) 2022-12-01
PH12014501565B1 (en) 2014-10-08
EP3527197B1 (en) 2022-09-07
DK3527196T3 (da) 2022-10-24
HUE060705T2 (hu) 2023-04-28
HRP20221431T1 (hr) 2023-01-06
EP3412277A1 (en) 2018-12-12
MX355729B (es) 2018-04-27
PL3412277T3 (pl) 2023-06-19
DK2806855T3 (en) 2018-09-03
US10028964B2 (en) 2018-07-24
ZA201405464B (en) 2015-12-23
NZ627837A (en) 2016-04-29
RS63952B1 (sr) 2023-02-28
SI3412277T1 (sl) 2023-03-31
PH12014501565A1 (en) 2014-10-08
HUE061566T2 (hu) 2023-07-28
CN105726548B (zh) 2019-05-14
MY165888A (en) 2018-05-18
US10946029B2 (en) 2021-03-16
CN104080444A (zh) 2014-10-01
TN2014000322A1 (en) 2015-12-21
EP3527199A1 (en) 2019-08-21
US8778402B2 (en) 2014-07-15
EP3527197A1 (en) 2019-08-21
EP2806855A1 (en) 2014-12-03
PE20141703A1 (es) 2014-11-24
US20180296573A1 (en) 2018-10-18
EP3020394A1 (en) 2016-05-18
WO2013110632A1 (en) 2013-08-01
US20150164915A1 (en) 2015-06-18
FI3412277T3 (fi) 2023-03-23
CO7010836A2 (es) 2014-07-31
KR20150089093A (ko) 2015-08-04
HRP20181550T1 (hr) 2018-11-30
IL233784A0 (en) 2014-09-30
HRP20221433T1 (hr) 2023-01-06
SG11201404350PA (en) 2014-08-28
KR101786586B1 (ko) 2017-10-18
AR089805A1 (es) 2014-09-17
EA031566B1 (ru) 2019-01-31
DK3527197T3 (da) 2022-10-24
ES2929137T3 (es) 2022-11-25
AU2013211656B2 (en) 2017-07-13
LT3412277T (lt) 2023-04-25
JP2015508416A (ja) 2015-03-19
DK3412277T3 (da) 2023-02-20
MX2014008631A (es) 2014-08-21
LT3527197T (lt) 2022-11-25
BR112014017481A8 (pt) 2021-06-15
CY1120684T1 (el) 2019-12-11
KR101560288B1 (ko) 2015-10-14
DK3527199T3 (da) 2022-10-24
HRP20221432T1 (hr) 2023-01-06
HUE060421T2 (hu) 2023-02-28
HUE060402T2 (hu) 2023-02-28
PT3527197T (pt) 2022-10-26
PL3527196T3 (pl) 2022-11-21
JP6104282B2 (ja) 2017-03-29
RS63761B1 (sr) 2022-12-30
CN105726548A (zh) 2016-07-06
EP3527199B1 (en) 2022-09-07
RS57637B1 (sr) 2018-11-30
SI2806855T1 (sl) 2018-11-30
EP3527196A1 (en) 2019-08-21
EA026267B1 (ru) 2017-03-31
KR20140114374A (ko) 2014-09-26
HK1200021A1 (en) 2015-07-31
MA35859B1 (fr) 2014-12-01
BR112014017481A2 (pt) 2017-06-13
PT3527199T (pt) 2022-11-08
CN104080444B (zh) 2017-06-20
HRP20230147T1 (hr) 2023-03-31

Similar Documents

Publication Publication Date Title
CL2014001966A1 (es) Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.
CL2011000696A1 (es) Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc
GT201400182A (es) Formulaciones farmacéuticas novedosas
GT200900098A (es) Aparato para dispersion de polvo, metodo para la fabricacion y uso del aparato y componentes que se pueden utilizar en el aparato y otros dispositivos
CL2014003286A1 (es) Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
GT201500218A (es) Compuesto
PE20141036A1 (es) Nueva dosificacion y formulacion
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
BR112017023351A2 (pt) composições multidrogas de matriz frágil
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
CL2014003361A1 (es) Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia.
EA201591871A1 (ru) Фармацевтическая композиция, содержащая будесонид и формотерол
TR200907913A2 (tr) İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
SG11201507651XA (en) Fine dry particulate resveratrol active agent compositions and topical formulations including the same
TR200907915A2 (tr) Kuru toz formunda farmasötik bileşim.
TR201714893A1 (tr) Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi.
TR201000730A2 (tr) Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.
TR201714725A1 (tr) Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu
TR201004317A2 (tr) Türbülans oluşumunu sağlayan inhalasyon cihazı.
AR098868A1 (es) Composición farmacéutica en polvo seco para inhalación
TR201000732A2 (tr) Tiotropyum ve budesonid içeren kuru toz formundaki farmasötik kompozisyon